Insider Trading Activity Kite Pharma, Inc. (NASDAQ:KITE) – EVP Sold 79,949 shares of Stock

0

Insider Trading Activity For Kite Pharma, Inc. (NASDAQ:KITE)

Helen Susan Kim , EVP of Kite Pharma, Inc. (NASDAQ:KITE) reportedly Sold 79,949 shares of the company’s stock at an average price of 119.56 for a total transaction amount of $9,558,702.44 SEC Form

Insider Trading History For Kite Pharma, Inc. (NASDAQ:KITE)

  • On 3/30/2015 Ran Nussbaum, Director, sold 193,730 with an average share price of $60.45 per share and the total transaction amounting to $11,710,978.50.View SEC Filing
  • On 4/27/2015 Cynthia M Butitta, CFO, sold 10,000 with an average share price of $59.76 per share and the total transaction amounting to $597,600.00.View SEC Filing
  • On 6/1/2015 Ran Nussbaum, Director, sold 80,760 with an average share price of $55.34 per share and the total transaction amounting to $4,469,258.40.View SEC Filing
  • On 6/1/2015 Marc Better, VP, sold 9,000 with an average share price of $54.60 per share and the total transaction amounting to $491,400.00.View SEC Filing
  • On 6/2/2015 Ran Nussbaum, Director, sold 305,434 with an average share price of $55.35 per share and the total transaction amounting to $16,905,771.90.View SEC Filing
  • On 6/15/2015 Rizwana F Sproule, VP, sold 9,567 with an average share price of $56.98 per share and the total transaction amounting to $545,127.66.View SEC Filing
  • On 6/15/2015 Margo R Roberts, Insider, sold 8,625 with an average share price of $56.99 per share and the total transaction amounting to $491,538.75.View SEC Filing
  • Analyst Ratings For Kite Pharma, Inc. (NASDAQ:KITE)
    These are 1 Sell Rating, 6 Hold Ratings, 9 Buy Ratings .
    The current consensus rating for Kite Pharma, Inc. (NASDAQ:KITE) is Buy (Score: 2.50) with a consensus target price of $89.00 , a potential (26.20% downside)

    Analyst Ratings History For Kite Pharma, Inc. (NASDAQ:KITE)

    • On 8/14/2015 Guggenheim Reiterated Rating Buy
    • On 3/20/2016 SunTrust Banks, Inc. Reiterated Rating Buy with a price target of $70.00
    • On 8/9/2016 Mizuho Set Price Target of rating Buy with a price target of $80.00
    • On 9/27/2016 Barclays PLC Boost Price Target of rating Equal Weight with a price target of $60.00 to $65.00
    • On 2/22/2017 Wells Fargo & Company Initiated Coverage of rating Market Perform to Market Perform
    • On 3/2/2017 Citigroup Inc. Downgraded rating Buy to Neutral with a price target of $62.00 to $87.00
    • On 3/6/2017 Royal Bank Of Canada Boost Price Target of rating Outperform with a price target of $85.00 to $95.00

    Recent Trading Activity for Kite Pharma, Inc. (NASDAQ:KITE)
    Shares of Kite Pharma, Inc. closed the previous trading session at 120.60 down -0.38 -0.31% with 954,574 shares trading hands.